Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Human Cancer Biology

Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3

Hilda Mujcic, Anika Nagelkerke, Kasper M.A. Rouschop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenna Sykes, Richard P. Hill, Marianne Koritzinsky and Bradly G. Wouters
Hilda Mujcic
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anika Nagelkerke
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasper M.A. Rouschop
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Chung
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naz Chaudary
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul N. Span
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blaise Clarke
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Milosevic
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenna Sykes
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard P. Hill
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Koritzinsky
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradly G. Wouters
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
1Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network; Departments of 2Laboratory Medicine and Pathobiology, 3Radiation Oncology, and 4Medical Biophysics; 5Radiation Medicine Program, 6Department of Biostatistics, Princess Margaret Cancer Centre, 7Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 8Maastricht Radiation Oncology (MaastRO) Lab, GROW – School for Oncology and Developmental Biology, Maastricht University, Maastricht; and 9Departments of Radiation Oncology and Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-13-0526 Published November 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Conditions of poor oxygenation (hypoxia) are present in many human tumors, including cervix cancer, and are associated with increased risk of metastasis and poor prognosis. Hypoxia is a potent activator of the PERK/eIF2α signaling pathway, a component of the unfolded protein response (UPR) and an important mediator of hypoxia tolerance and tumor growth. Here, the importance of this pathway in the metastasis of human cervix carcinoma was investigated.

Experimental Design: Amplification and expression of LAMP3, a UPR metastasis-associated gene, was examined using FISH and immunofluorescence in a cohort of human cervix tumors from patients who had received oxygen needle electrode tumor oxygenation measurements. To evaluate the importance of this pathway in metastasis in vivo, we constructed a series of inducible cell lines to interfere with PERK signaling during hypoxia and used these in an orthotopic cervix cancer model of hypoxia-driven metastasis.

Results: We show that LAMP3 expression in human cervix tumors is augmented both by gene copy number alterations and by hypoxia. Induced disruption of PERK signaling in established orthotopic xenografts resulted in complete inhibition of hypoxia-induced metastasis to the lymph nodes. This is due, in part, to a direct influence of the UPR pathway on hypoxia tolerance. However, we also find that LAMP3 is a key mediator of hypoxia-driven nodal metastasis, through its ability to promote metastatic properties including cell migration.

Conclusion: These data suggest that the association between hypoxia, metastasis, and poor prognosis is due, in part, to hypoxic activation of the UPR and expression of LAMP3. Clin Cancer Res; 19(22); 6126–37. ©2013 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received February 26, 2013.
  • Revision received August 23, 2013.
  • Accepted September 12, 2013.
  • ©2013 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 19 (22)
November 2013
Volume 19, Issue 22
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Hilda Mujcic, Anika Nagelkerke, Kasper M.A. Rouschop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenna Sykes, Richard P. Hill, Marianne Koritzinsky and Bradly G. Wouters
Clin Cancer Res November 15 2013 (19) (22) 6126-6137; DOI: 10.1158/1078-0432.CCR-13-0526

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Hilda Mujcic, Anika Nagelkerke, Kasper M.A. Rouschop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenna Sykes, Richard P. Hill, Marianne Koritzinsky and Bradly G. Wouters
Clin Cancer Res November 15 2013 (19) (22) 6126-6137; DOI: 10.1158/1078-0432.CCR-13-0526
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sirt7 Promotes Colorectal Cancer Tumorigenesis
  • Contact Guidance Controls T-cell Migration in PDAC
  • MET in Papillary RCC
Show more Human Cancer Biology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement